New anti-tuberculosis drugs for special populations: a difficult-to-address issue

Affiliations

¹ Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences - University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy giovannibattista.migliori@fsm.it.
² Dept of Infectious Diseases, Galliera Hospital, Genova, Italy.
³ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.
⁴ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland.

Free article

Comment

Giovanni Sotgiu et al. Eur Respir J. 2016 Sep.

Free article

. 2016 Sep;48(3):957-8.

doi: 10.1183/13993003.01289-2016.

¹ Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences - University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy giovannibattista.migliori@fsm.it.
² Dept of Infectious Diseases, Galliera Hospital, Genova, Italy.
³ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.
⁴ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland.

No abstract available

Comment on

Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Pontali E, et al. Eur Respir J. 2016 Feb;47(2):394-402. doi: 10.1183/13993003.01891-2015. Eur Respir J. 2016. PMID: 26828052 No abstract available.
Paediatric study of bedaquiline remains an "open issue".
McKenna L, Ruiz Mingote L. McKenna L, et al. Eur Respir J. 2016 Sep;48(3):956-7. doi: 10.1183/13993003.00628-2016. Eur Respir J. 2016. PMID: 27581412 No abstract available.